Quick Answer
Kalaris Therapeutics, Inc. reported Total Assets of $121.74 million for fiscal year 2025.
Kalaris Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $121.74M | +1875.6% |
| 2024 | $6.16M | -96.8% |
| 2023 | $190.80M | -31.1% |
| 2022 | $277.08M | -3.3% |
| 2021 | $286.59M | -22.7% |
| 2020 | $370.82M | +166.0% |
| 2019 | $139.42M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $81.17M | -33.8% | -12.6% |
| June 30, 2025 | $92.84M | -29.1% | -9.9% |
| March 31, 2025 | $103.09M | -28.5% | +1573.0% |
| December 31, 2024 | $6.16M | -96.8% | -95.0% |
| September 30, 2024 | $122.53M | -50.7% | -6.5% |
| June 30, 2024 | $130.99M | -53.7% | -9.1% |
| March 31, 2024 | $144.14M | -40.9% | -24.5% |
| December 31, 2023 | $190.80M | -31.1% | -23.2% |
- Kalaris Therapeutics, Inc. showed an increase of +1875.6% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Kalaris Therapeutics, Inc.’s total assets has declined by 12.7% (from $139.42 million to $121.74 million).
- The most recent figure is from Kalaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: